SPX3,783.28-7.65 -0.20%
DIA302.79-0.35 -0.12%
IXIC11,148.64-27.77 -0.25%

Vaxxinity Starts Dosing In Phase 1 Migraine Vaccine Trial

Benzinga · 09/13/2022 11:58
  • Vaxxinity Inc (NASDAQ:VAXX) announced that the first subjects had been dosed in the Phase 1 clinical trial of UB-313, a vaccine targeting calcitonin gene-related peptide (CGRP), for the preventive treatment of migraine.
  • The Phase 1 randomized, placebo-controlled, double-blind, multidose trial will enroll approximately 40 healthy volunteers in Belgium. 
  • The trial's objectives are to evaluate safety, tolerability, and immunogenicity. Serum anti-CGRP antibody titers will measure immunogenicity. Pharmacodynamics of the immune response will be measured by the inhibition of the capsaicin-induced increase in dermal blood flow, an established model of target engagement in migraine.
  • Price Action: VAXX shares are trading 2.09% higher at $2.20 on the last check Tuesday.